Jury Blames J&J Baby Powder for Woman’s Fatal Ovarian Cancer

Gayle Emerson used J&J’s baby powder for more than 45 years. Diagnosed with ovarian cancer in 2015 at age 64, she filed a lawsuit in 2019, alleging that asbestos-contaminated talc in the product caused her illness. She died just six months later, and her family continued her claim as a wrongful death lawsuit.

After a three-week trial in the Philadelphia Court of Common Pleas, jurors found in favor of Emerson’s estate. They awarded $50,000 in compensatory damages and $200,000 in punitive damages, concluding that the company’s products caused her cancer and that the company failed to adequately warn consumers of the risks.

At trial, attorneys for the Emerson family argued that the company knew for decades that its talc products could contain asbestos—a known carcinogen—but failed to disclose that risk to regulators or the public. They presented internal documents and expert testimony suggesting the company had identified contamination concerns as early as the 1960s.

The defense disputed those claims, maintaining that its talc products are safe, asbestos-free, and do not cause cancer. Company attorneys pointed to alternative explanations for Emerson’s illness, including age-related factors and naturally occurring risks.

However, the jury sided with the plaintiff’s interpretation of the scientific evidence. More than 30 peer-reviewed studies have identified a statistical association between talcum powder use and ovarian cancer. A 2024 National Institutes of Health study similarly found an increased risk linked to genital talc use.

The admissibility of such expert testimony has been a key battleground in these lawsuits. In January 2026, a federal judge overseeing multidistrict litigation reaffirmed that plaintiffs’ experts could testify about the connection between talc and ovarian cancer, noting that the majority of recent studies support that association.

During closing arguments, plaintiff attorney Leigh O’Dell described Johnson & Johnson’s baby powder as the “cornerstone” or “sacred cow” of the company—arguing that corporate loyalty to the product outweighed consumer safety. After deliberating for more than three days, the jury agreed.

First Plaintiff Win in Philadelphia Talc Litigation

The Emerson verdict is particularly notable as the first plaintiff victory in Philadelphia’s talc litigation docket, which includes about 175 cases. For months, these cases had been largely stalled amid Johnson & Johnson’s efforts to resolve claims through a global settlement tied to a controversial bankruptcy maneuver. That strategy—often referred to as the “Texas Two-Step”—involved shifting talc liabilities to a subsidiary that would then seek Chapter 11 protection. Courts rejected the approach multiple times, most recently in 2025, allowing cases to resume nationwide.

With trials back underway, early outcomes are drawing attention. This ruling follows another recent ovarian cancer verdict against the company and could influence how remaining cases proceed in 2026.

Mounting Losses—and Growing Pressure

Although the $250,000 award is relatively small, it adds to a growing list of courtroom losses for J&J. In late 2025, juries in California and Maryland returned verdicts totaling more than $2 billion in mesothelioma cases tied to talc exposure. Another ovarian cancer case in December resulted in a $40 million award.

These outcomes are unfolding against a backdrop of massive litigation. As of early 2026, more than 67,000 ovarian cancer claims were pending in federal court, with thousands more filed in state courts. Across all talc-related claims—including mesothelioma—total filings exceed 90,000.

The scale of liability has forced J&J to reassess its legal strategy. After its bankruptcy-based settlement plan collapsed, the company announced it would instead fight claims in court, calling them “meritless” and based on “junk science.”

So far, that approach has yet to yield a decisive courtroom victory. Legal observers say continued losses could eventually push the company back toward settlement negotiations. Each plaintiff win—regardless of size—adds pressure by reinforcing the credibility of claims and increasing financial exposure.

A Turning Point for Ovarian Cancer Claims?

Historically, many of the largest talc verdicts have involved mesothelioma, a cancer strongly linked to asbestos exposure. Ovarian cancer cases have been more contested, with mixed outcomes and ongoing scientific debate. Recent rulings, including Emerson’s, suggest that juries may be increasingly willing to find causation in ovarian cancer claims as well.

More trials are expected throughout 2026 as courts work through the backlog of cases. Key issues—such as the strength of scientific evidence, corporate knowledge of contamination risks, and the adequacy of product warnings—will continue to shape outcomes.

Meanwhile, J&J has already taken steps to distance itself from the controversy. The company stopped selling talc-based baby powder in the U.S. in 2020 and globally in 2023, replacing it with a cornstarch-based formulation.

For plaintiffs and their families, cases like Emerson’s represent more than compensation—they are a measure of accountability. And as juries continue to weigh evidence in courtrooms across the country, the broader question persists: whether one of the most iconic consumer products in American history carried risks that were never fully disclosed.